Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The challenge of rapid diagnosis in oncology: Diagnostic accuracy and cost analysis of a large-scale one-stop breast clinic.
Delaloge S, Bonastre J, Borget I, Garbay JR, Fontenay R, Boinon D, Saghatchian M, Mathieu MC, Mazouni C, Rivera S, Uzan C, André F, Dromain C, Boyer B, Pistilli B, Azoulay S, Rimareix F, Bayou el-H, Sarfati B, Caron H, Ghouadni A, Leymarie N, Canale S, Mons M, Arfi-Rouche J, Arnedos M, Suciu V, Vielh P, Balleyguier C. Delaloge S, et al. Among authors: ghouadni a. Eur J Cancer. 2016 Oct;66:131-7. doi: 10.1016/j.ejca.2016.06.021. Epub 2016 Aug 26. Eur J Cancer. 2016. PMID: 27569041
[Molecular signatures of breast cancer: What clinical utility?].
Delaloge S, Saghatchian M, Ghouadni A, Fekih M, André F. Delaloge S, et al. Among authors: ghouadni a. Bull Cancer. 2015 Jun;102(6 Suppl 1):S102-5. doi: 10.1016/S0007-4551(15)31227-3. Bull Cancer. 2015. PMID: 26118866 French.
Ki67--no evidence for its use in node-positive breast cancer.
Andre F, Arnedos M, Goubar A, Ghouadni A, Delaloge S. Andre F, et al. Among authors: ghouadni a. Nat Rev Clin Oncol. 2015 May;12(5):296-301. doi: 10.1038/nrclinonc.2015.46. Epub 2015 Mar 17. Nat Rev Clin Oncol. 2015. PMID: 25781576 Review.
Higher antitumor activity of trabectedin in germline BRCA2 carriers with advanced breast cancer as compared to BRCA1 carriers: A subset analysis of a dedicated phase II trial.
Ghouadni A, Delaloge S, Lardelli P, Kahatt C, Byrski T, Blum JL, Gonçalves A, Campone M, Nieto A, Alfaro V, Cullell-Young M, Lubinski J. Ghouadni A, et al. Breast. 2017 Aug;34:18-23. doi: 10.1016/j.breast.2017.04.006. Epub 2017 Apr 30. Breast. 2017. PMID: 28467918 Clinical Trial.